


Attorney Docket No.: DEX-0245
Inventors: Recipon et al.
Serial No.: 10/034,934
Filing Date: October 26, 2001
Page 3

REMARKS

This Preliminary Amendment is being filed to correct an inadvertent typographical error in claims 14 and 15. Specifically, claims 14 and 15 have been amended to depend from claims 1 and 11. In addition, the priority data has been amended in accordance with the executed Declaration and Power of Attorney form filed May 28, 2002, to claim priority only to U.S. Provisional Application Serial No. 60/243,461, filed October 26, 2000. No new matter has been added by these amendments. Entry of these amendments is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: May 29, 2002

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, NJ 08053
856-810-1515

Attorney Docket No.: DEX-0245
Inventors: Recipon et al.
Serial No.: 10/034,934
Filing Date: October 26, 2001
Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

Please replace the paragraph at page 1, lines 4-7, as follows:

--This application claims the benefit of priority from U.S. Provisional Application Serial No. 60/243,461 filed October 26, 2000, ~~U.S. Provisional Application No. 60/252,055, filed November 20, 2000, and U.S. Provisional Application No. 60/252,496, filed November 22, 2000,~~ which ~~are~~ is herein incorporated by reference in ~~their~~ its entirety.--

In the claims:

Please amend claims 14 and 15 as follows:

14. (amended) A method for diagnosing and monitoring the presence and metastases of lung cancer in a patient, comprising the steps of:

(a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of claim ~~6~~ 11 in a sample of a patient; and

(b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to

Attorney Docket No.: DEX-0245
Inventors: Recipon et al.
Serial No.: 10/034,934
Filing Date: October 26, 2001
Page 5

the amount of the lung specific marker in a normal control;
wherein a difference in the amount of the nucleic acid molecule
or the polypeptide in the sample compared to the amount of the
nucleic acid molecule or the polypeptide in the normal control is
associated with the presence of lung cancer.

15. (amended) A kit for detecting a risk of cancer or
presence of cancer in a patient, said kit comprising a means for
determining the presence the nucleic acid molecule of claim 1 or
a polypeptide of claim ~~6~~ 11 in a sample of a patient.